Spyre Therapeutics (SYRE) Non-Current Deffered Revenue (2021 - 2023)

Spyre Therapeutics (SYRE) has 3 years of Non-Current Deffered Revenue data on file, last reported at $2.3 million in Q2 2023.

• For the quarter ending Q2 2023, Non-Current Deffered Revenue fell 1.31% year-over-year to $2.3 million; the trailing twelve-month figure through Jun 2023 stood at $2.3 million (down 1.31% YoY), and the FY2022 full-year result was $2.2 million, up 79.05% from the prior year.
• Non-Current Deffered Revenue for Q2 2023 stood at $2.3 million, roughly flat from $2.3 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $2.4 million in Q2 2022 and bottomed at $740000.0 in Q1 2022.
• The 3-year median for Non-Current Deffered Revenue is $2.2 million (2021), against an average of $2.0 million.
• The widest annual swing landed in 2022, when Non-Current Deffered Revenue plunged 67.46%; it then jumped 216.35% in 2023.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $1.2 million in 2021, then soared by 79.05% to $2.2 million in 2022, then increased by 7.43% to $2.3 million in 2023.
• The last three Non-Current Deffered Revenue figures came in at $2.3 million (Q2 2023), $2.3 million (Q1 2023), and $2.2 million (Q4 2022), per Business Quant data.

Peer Comparison